Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Hexagon Capital Partners LLC

Hexagon Capital Partners LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 49.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 309 shares of the company’s stock after selling 301 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Moderna were worth $33,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of MRNA. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna during the fourth quarter worth $27,000. Arlington Trust Co LLC increased its holdings in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Rise Advisors LLC raised its position in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after acquiring an additional 116 shares during the period. Finally, CVA Family Office LLC raised its position in shares of Moderna by 242.3% in the first quarter. CVA Family Office LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 315 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on MRNA shares. Oppenheimer increased their price target on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Evercore ISI reissued an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. UBS Group increased their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Piper Sandler reissued an “overweight” rating and set a $214.00 target price on shares of Moderna in a research note on Thursday, June 27th. Finally, Royal Bank of Canada raised their price target on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $134.02.

Moderna Stock Performance

Shares of Moderna stock opened at $115.95 on Tuesday. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a 50 day moving average of $134.36 and a 200 day moving average of $112.40.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the previous year, the firm posted $0.19 earnings per share. The company’s revenue was down 91.0% compared to the same quarter last year. On average, research analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Insider Activity

In related news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the completion of the sale, the president now owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the sale, the president now owns 1,486,241 shares of the company’s stock, valued at $156,085,029.82. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 202,832 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the transaction, the director now owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 411,255 shares of company stock worth $56,118,931. 15.20% of the stock is currently owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.